1. Home
  2. NSPR vs PRPO Comparison

NSPR vs PRPO Comparison

Compare NSPR & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo InspireMD Inc.

NSPR

InspireMD Inc.

HOLD

Current Price

$0.72

Market Cap

33.7M

Sector

Health Care

ML Signal

HOLD

Logo Precipio Inc.

PRPO

Precipio Inc.

HOLD

Current Price

$24.10

Market Cap

40.1M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
NSPR
PRPO
Founded
2005
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Laboratory Analytical Instruments
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
33.7M
40.1M
IPO Year
2009
2000

Fundamental Metrics

Financial Performance
Metric
NSPR
PRPO
Price
$0.72
$24.10
Analyst Decision
Buy
Analyst Count
1
0
Target Price
$4.00
N/A
AVG Volume (30 Days)
39.9K
97.8K
Earning Date
05-04-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
92.15
EPS
N/A
N/A
Revenue
$2,310,000.00
$24,049,000.00
Revenue This Year
$57.98
N/A
Revenue Next Year
$95.41
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
29.77
52 Week Low
$0.63
$13.80
52 Week High
$2.59
$33.63

Technical Indicators

Market Signals
Indicator
NSPR
PRPO
Relative Strength Index (RSI) 51.86 50.87
Support Level $0.69 $22.36
Resistance Level $0.72 $25.27
Average True Range (ATR) 0.03 1.59
MACD 0.01 0.05
Stochastic Oscillator 89.14 76.67

Price Performance

Historical Comparison
NSPR
PRPO

About NSPR InspireMD Inc.

InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.

About PRPO Precipio Inc.

Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. Its objective is to enhance diagnostic accuracy & accessibility while building a sustainable business model that supports ongoing innovation. The company operates Clinical Laboratory Improvement Amendments laboratories in both New Haven, Connecticut, & Omaha, Nebraska, providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. The company operates in a single segment, which includes two divisions: the Pathology Services Division & the Products Division. The Pathology Services provides specialized cancer diagnostic testing services. The pathology services division specializes in diagnostic testing focused mainly on hematologic cancers.

Share on Social Networks: